Digital medicine pioneer aims to revolutionize life sciences and healthcare data synthesis through AI-driven data connections and collaborations with clinical-grade compliance.
Betteromics which has developed a clinical-grade compliant Software-as-a-Service platform that empowers life sciences professionals with the latest AI and computational techniques, announced that it has raised $20 million in a Series A financing led by Sofinnova Partners and Triatomic Capital, with participation from SHAKTI.
The company’s Omics AI Cloud platform, which can be deployed privately, eliminates data silos, allowing users to analyze multi-modal, multi-omics data in one place. It reduces risk and increases velocity from data generation to AI-powered insights.
The financing will expand the Betteromics team, and scale marketing and sales efforts to life science companies, ranging from startups to the largest enterprises.
The company’s top executives — Angela Lai as Founder and Chief Executive Officer (CEO), Chetan Patel as Chief Technology Officer, and Jack Menzel as Chief Product Officer — were integral in building transformative infrastructure that powers products at Google and GRAIL.
Lai said, “The industry has succeeded in finding ways to measure every omic and every analyte, but traditional methods and legacy systems have kept that data in silos, failing to unlock its immense potential. We’ve solved that.”
Betteromics was founded in 2020 with a mission to enable scientists, researchers, and clinicians to understand and gain insights from massive amounts of data using advanced computation and AI techniques. The Omics AI Cloud streamlines the creation of knowledge graphs, integrating and connecting data with emerging standards and ontologies from disparate silos. The platform is tailored to a range of users: from diagnostic and therapeutic product developers to biotech manufacturers needing real-time quality monitoring.
Designed with compliance at its core, the Betteromics platform is certified to ISO 9001 and ISO 27001, SOC2 Type II and HITRUST i1, so that from day 1 users can ensure traceability and reproducibility for all data and analysis performed, allowing clients to operate their data knowing there are rigorous protocols in place for their most valuable and sensitive data assets.
Jeff Huber, Partner at Triatomic Capital, said: “The most meaningful application of AI technology is in life sciences. The Betteromics team is uniquely positioned with their translational experience from building the lab, data, clinical, and machine learning platform that powered the largest clinical studies ever done to reduce risk and increase velocity from data generation to AI-powered insight for life sciences companies of all sizes.”
Edward Kliphuis, Partner at Sofinnova Partners, said: “Betteromics uniquely merges data science and human expertise in life sciences. The team brings together a rare combination of outstanding developers, data experts, and AI mavens with deep experience in the life sciences. Their groundbreaking approach to leveraging computational techniques on multi-omics datasets promises to bring unprecedented new insights and is poised to transform healthcare as we know it.”
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
